Acumen Pharmaceuticals(ABOS) - 2022 Q4 - Earnings Call Presentation

Clinical Trial Update - Enrollment in the INTERCEPT-AD Phase 1 clinical trial of ACU193 for early Alzheimer's disease (AD) is complete[5] - Topline results, safety data, and clinical proof-of-mechanism from the INTERCEPT-AD trial are expected in Q3 2023[5] - Preliminary data showed higher-than-expected ACU193 exposures at all dose levels[5] - Preliminary results from Cohort 3 (SAD 25 mg/kg) showed Day 21 cerebrospinal fluid (CSF) ACU193 levels exceeding reported soluble amyloid beta oligomer (AβO) levels[5] - Two blinded observations of asymptomatic ARIA-E influenced the decision to amend Cohort 7 dose[5] - The company is actively preparing for Phase 2/3 activities, anticipating successful Phase 1 results[5] - An end-of-Phase 2 meeting with the FDA is planned for Q4 2023 to discuss the Phase 2/3 study design[5] Financial Position - As of December 31, 2022, Acumen had approximately $193 million in cash, cash equivalents, and marketable securities[7] - The company believes it has sufficient resources to advance ACU193 through 2025[7]